Drug containing recombinant mistletoe lectins for treating

Abstract

The invention relates to a drug and/or pharmaceutical composition for treating metastatic tumors, in particular of malignant melanoma, above all of stage IV malignant melanoma, and to the use of said drug, in particular the use of said drug in select patient populations.

1 - 14 . (canceled) 
     
     
         15 . A drug containing purified recombinant mistletoe lectin for treating metastatic tumors or skin cancer, wherein the purified recombinant mistletoe lectin is selected from the group of amino acid sequences of SEQ ID Nos. 1-12, or is a combination thereof. 
     
     
         16 . The drug according to  claim 15 , wherein the purified recombinant mistletoe lectin polypeptide is a mistletoe lectin A-chain selected from the group of amino acid sequences of SEQ ID No. 1-3, or is a combination thereof. 
     
     
         17 . The drug according to  claim 15 , wherein the purified recombinant mistletoe lectin polypeptide is a mistletoe lectin B-chain selected from the group of amino acid sequences of SEQ ID No. 4-12, or is a combination thereof. 
     
     
         18 . The drug according to  claim 15 , wherein the metastatic tumor or skin cancer is malignant melanoma. 
     
     
         19 . The drug according to  claim 15 , wherein the drug is selected for non-responders and therapeutic failures of a standard tumor therapy. 
     
     
         20 . The drug according to  claim 15 , wherein the drug is selected for the treatment of stages Ill and IV of a metastatic tumor or skin cancer. 
     
     
         21 . The drug according to  claim 20 , wherein the metastatic tumor or skin cancer is malignant melanoma. 
     
     
         22 . The drug according to  claim 15 , wherein the drug is used after a first standard treatment for tumors. 
     
     
         23 . The drug containing a purified recombinant mistletoe lectin polypeptide according to  claim 15 , optionally in combination with a pharmaceutically compatible carrier. 
     
     
         24 . The drug containing a purified recombinant mistletoe lectin polypeptide according to  claim 15  for the specific treatment of malignant melanoma in humans, wherein the drug is used in a dosage in a range of 3-7 ng recombinant mistletoe lectin per kg body weight. 
     
     
         25 . The drug according to  claim 24 , wherein the drug is used in a dosage of 5 ng recombinant mistletoe lectin per kg body weight. 
     
     
         26 . The drug containing a purified recombinant mistletoe lectin polypeptide according to  claim 15  for the specific treatment of malignant melanoma in humans, wherein the dosage of recombinant mistletoe lectin is 200-500 ng, independently of body weight. 
     
     
         27 . The drug according to  claim 26 , wherein the dosage of purified recombinant mistletoe lectin is 350 ng, independently of body weight. 
     
     
         28 . The drug according to  claim 15 , wherein the drug is administered at least once a week. 
     
     
         29 . The drug according to  claim 15 , wherein the drug is administered at least twice a week, or at least three times per week. 
     
     
         30 . A pharmaceutical composition containing at least one recombinant mistletoe lectin according to  claim 15 , in combination with a pharmaceutically compatible carrier or, optionally, additional inactive ingredients and additives. 
     
     
         31 . A drug containing purified recombinant mistletoe lectin for treating metastatic tumors or skin cancer, wherein the purified recombinant mistletoe lectin is selected from the group of amino acid sequences of SEQ ID Nos. 2, 3, and 5-12, or is a combination thereof.